Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novartis AG Common Stock (NY:NVS)

109.59 +1.13 (+1.04%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
45 46 Next >
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,... 
Via FinancialNewsMedia
Exposures COVID-19
Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
Photo by Diana Polekhina on Unsplash 
Via Benzinga
Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests
Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH 
Via Benzinga
Why Are Pharming Shares Trading Higher Today?
Pharming Group NV (NASDAQ: PHAR) has annou 
Via Benzinga
Recap: Novartis Q4 Earnings
  Novartis (NYSE:NVS) reported its Q4 earnings results on Wednesday, February 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Carlyle, Blackstone Mull $25B Buyout For Novartis' Sandoz Arm: Report
Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Novartis AG's unit (NYSE: NVS) Sandoz,  
Via Benzinga
World Markets News for Wednesday
Gold and the Euro are up as the greenback loses traction. 
Via Talk Markets
Novartis Says Sandoz Future Uncertain As Generic Drug Sales Flounder
Novartis stock fell Wednesday on a disappointing fourth quarter. The company says it's still reviewing its generic drugs unit. 
Via Investor's Business Daily
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,  
Via Benzinga
Earnings Scheduled For February 2, 2022
Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is likely to report quarterly earnings at $1.57 per share on revenue of $24.59 billion. 
Via Benzinga
World Markets News for Tuesday
Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon. 
Via Talk Markets
The Last Day In January
The market is suspicious of the moves up to right matters. 
Via Talk Markets
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Fractional Investment Opportunity In Beachfront Multifamily Property: Last Call To Invest
Retail investors have the opportunity to own equity in Eliot on the Ocean, a 94% occupied multifamily mid-rise apartment complex along Revere Beach in Boston’s North Shore... 
Via Benzinga
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 24, 2022 – USA News Group – Within the grand battle against cancer, the use of immunotherapy continues to grow at... 
Via FinancialNewsMedia
A New Oral Therapy for Psoriasis Could Be Coming Soon
Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice... 
Via Benzinga
Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026 – Key Players are Johnson & Johnson (US), Novartis International AG (Switzerland)
Via AB Newswire
Exposures COVID-19
Chopped Stocks
The day's theme is sell tech and buy banks. 
Via Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus... 
Via Benzinga
7 Best Long-Term Stocks to Buy and Hold for the Next Decade
These seven long-term stocks are among the best picks for truly long-term investors looking for companies to hold for the next decade. 
Via InvestorPlace
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as... 
Via FinancialNewsMedia
Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data
After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates
Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were... 
Via Benzinga
Markets Inching Up
As both China and the SEC are cracking down on Variable Interest Entities raising funds as if they were stocks, these are now in the dumps. 
Via Talk Markets
3 Synthetic Biology Stocks In Focus With Strong Potential
Here we discuss three stocks engaged in the field of scientific biology that investors must follow, as they have the potential to generate wealth going forward. 
Via Talk Markets
Week In Review: BeiGene Out-Licenses TIGIT Inhibitor To Novartis In $2.8 Billion Pact
Beijing BeiGene out-licensed ex-China rights for its TIGIT inhibitor to Novartis in a multi-faceted $2.8 billion deal. As part of the agreement, BeiGene will have rights to market five Novartis... 
Via Talk Markets
Novartis' Cosentyx Scores FDA Approval For Arthritis In Children, Adolescents
The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) for active enthesitis-related arthritis (ERA) in four years and older, and active juvenile... 
Via Benzinga
FDA Approves Alnylam - Novartis' Leqvio As the First siRNA To Reduce Bad Cholesterol
The FDA has approved Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Leqvio (inclisiran) to lower low-density lipoprotein cholesterol (LDL-C). Leqvio is... 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.